Evidence map›Paper›PMID 35460294›Full record

SynthesisDiabetic medicine : a journal of the British Diabetic Association2022

Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus.

Wajd Alkabbani, Arsène Zongo, Jasjeet K Minhas-Sandhu, Dean T Eurich, Baiju R Shah, Mhd Wasem Alsabbagh, John-Michael Gamble

Open access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetic medicine : a journal of the British Diabetic Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Wajd AlkabbaniSchool of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.ORCID 0000-0002-7030-0442
Arsène ZongoFaculty of Pharmacy, Université Laval, Quebec, QC, Canada.
Jasjeet K Minhas-SandhuSchool of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.
Dean T EurichSchool of Public Health, University of Alberta, Edmonton, AB, Canada.ORCID 0000-0003-2197-0463
Baiju R ShahDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0003-3598-3628
Mhd Wasem AlsabbaghSchool of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.
John-Michael GambleSchool of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.ORCID 0000-0001-6891-8721
University of Waterloo · CASunnybrook Health Science Centre · CAUniversité Laval · CAUniversity of Alberta · CA

Funding

Canadian Institute of Health Research FRN 156064
6 · The paper itself

Abstract

aimTo assess the association between SGLT-2 inhibitors initiation and genital tract infections (GTIs) among patients with type 2 diabetes.

methodsA population-based cohort study using administrative healthcare data from Alberta, Canada, and primary care data from the UK's Clinical Practice Research Datalink (CPRD). Among new metformin users, we identified new users of SGLT-2 inhibitors and five active comparator cohorts (new users of dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas (SU), glucagon-like peptide-1 receptor agonists (GLP-1 RA), thiazolidinediones (TZD) and insulin). The outcome of interest was a composite GTI outcome. In each cohort, we used high-dimensional propensity score matching to adjust for confounding and conditional Cox proportional hazards regression to estimate the hazard ratios (HR). We used random-effects meta-analysis to combine aggregate data across databases.

resultsThe risk of GTI was higher for SGLT-2 inhibitors users compared with DPP4inhibitor users (pooled HR 2.68, 95% CI 2.19 3.28), SU users (3.29, 2.62-4.13), GLP1-RA users (2.51, 1.90-3.31), TZD users (4.17, 2.46-7.08) and insulin users (1.86, 1.27-2.73).

conclusionIn five comparative cohorts, SGLT-2 inhibitors initiation is associated with a higher risk of GTIs. These findings from real-world data are consistent with placebo-controlled randomized controlled trials.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsReproductive Tract InfectionsSodium-Glucose Transporter 2 InhibitorsAlbertaCohort StudiesGlucagon-Like Peptide-1 Receptor AgonistsGlucoseHumansHypoglycemic AgentsInsulinSodiumSulfonylurea CompoundsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsGlucoseHypoglycemic AgentsInsulinSodiumSodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsCohortComparative safetyGenital tract infectionsSGLT-2 Inhibitors

Identifiers

PMID35460294
PMCPMC9546240
OpenAlexW4224327037

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.